Chugai Pharmaceutical Co., Ltd. · TSE:4519
Chugai Pharmaceutical — Q1 2014 Earnings Presentation
17 slides from Chugai Pharmaceutical's earnings presentation, Apr 24, 2014
Slide 1: FY2014 1Q Consolidated Financial Overview (IFRS based)
FY2014 1Q Consolidated C lid t d Financial Fi i l Overview O i (IFRS based) CHUGAI PHARMACEUTICAL CO., LTD. E Executive ti Vice Vi P President id t CFO Yoshio Itaya April 24, 2014
Slide 2: Forward-Looking Statements
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2014 1Q Consolidated Financial Overview Forward Looking Statements Forward-Looking This presentation may include forward-looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co.
Slide 3: Summary
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2014 1Q Consolidated Financial Overview Summary Revenues: 124.0 billion JPY (+37.2% YoY) • Domestic sales excl excl. Tamiflu (+23.8%): (+23 8%): double-digit double digit increase due to steady growth of mai
Slide 4: IFRS and Core Results Jan – Mar
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2014 1Q Consolidated Financial Overview IFRS and Core Results Jan – Mar IFRS results Non-core items Core results 2014 Intangible assets Other 2014 (Billion JPY) Non-Core items and Business eliminated Jan - Mar
Slide 5: Financial Overview Jan – Mar: Year on Year (Core)
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2014 1Q Consolidated Financial Overview Year on Year (Core) Financial Overview Jan – Mar 2013 2014 (Billion JPY) ((Billion JPY)) Jan - Mar Jan - Mar Growth vs. Rev*. vs. Rev*. Royalties and other operating inc
Slide 6: Sales (excl. Tamiflu) Jan – Mar: Year on Year
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2014 1Q Consolidated Financial Overview Year on Year Sales (excl (excl. Tamiflu) Jan – Mar Sales excl. Tamiflu (Billion JPY) 107.3 (+28.6, +36.3%) Actemra Overseas O 22.1 -0.7 Epogin (overseas) +11.9 +12.2, +1
Slide 7: Tamiflu Sales Performance
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2014 1Q Consolidated Financial Overview Tamiflu Sales Performance Fiscal Term Sales Forecast (Billion JPY) FY2009 12 FY2009.12 FY2010 12 FY2010.12 FY2011 12 FY2011.12 FY2012 12 FY2012.12 FY2013 12 FY2013.12 FY
Slide 8: Operating Profit Jan – Mar: Year on Year (Core)
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2014 1Q Consolidated Financial Overview Year on Year (Core) Operating Profit Jan – Mar 2013 2014 (Billion JPY) (Billion JPY) Growth Jan - Mar Ja a Ja Jan - Mar a Revenues 90.4 124.0 +33.6 Royalties and other M
Slide 9: Financial Overview Jan – Mar: vs. Forecast (Core)
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2014 1Q Consolidated Financial Overview vs. Forecast (Core) Financial Overview Jan – Mar Actual Forecast on Jan 30 2013 (Billion JPY) 2014 2014 Progress Progress* Jan - Mar Jan - Dec Revenues 124.0 451.0 27.5%
Slide 10: Domestic Sales (excl. Tamiflu) Jan – Mar: vs. Forecast
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2014 1Q Consolidated Financial Overview vs. Forecast (Core) Domestic Sales (excl (excl. Tamiflu) Jan – Mar Actual Forecast on Jan 30 2013 (Billion JPY) 2014 2014 P Progress P Progress* * Jan - Mar Jan - Dec Do
Slide 11: Impact from Foreign Exchange
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ FY2014 1Q Consolidated Financial Overview vs. Forecast (Core) Impact from Foreign Exchange Reference Assumption Jan - Dec FX rate to the JPY Actual Jan - Mar avg. Actual Jan - Mar avg. (as of Jan. 30) (2013) 1CH
Slide 12: Overview of Development Pipeline
Aiming to become “Top Pharmaceutical Company” O Overview i off Development D l t Pipeline Pi li CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President Head of Project & Lifecycle Management Unit Yutaka Tanaka April 24, 2014
Slide 13: Oncology Field Projects under Development
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ Overview of Development Pipeline Oncology Field Projects under Development (as of 24 April, 2014) Phase I Phase II Phase III Filed CKI27 / RG7304 GC33 / RG7686 RG1273 / Perjeta AF802 (RG7853) / alectinib (Japan
Slide 14: Primary Field Projects under Development
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ Overview of Development Pipeline Primary Field Projects under Development (as of 24 April, 2014) Phase I Phase II Phase III Filed Bone RG484 / Bonviva (oral) - osteoporosis & NRD101 / Suvenyl Joint - enthesopath
Slide 15: Development Status
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ Overview of Development Pipeline D Development l t St Status t In- RG3502 / Kadcyla® : licensed - Launched in April 2014 (Indication: Breast Cancer) - Expected indication: Breast Cancer (adjuvant) Started Global
Slide 16: Development Status
ACCEL 15 Aiming to become “Top Pharmaceutical Company” ~Innovation all for the patients~ Overview of Development Pipeline D Development l t St Status t In- SA237 ((anti-IL-6R MAb)) : house Expected indication: Neuromyelitis Optica Started Global P3 in February 2014 (managed by Chugai) In- ACE910 (an
Slide 17: Contacts: Corporate Communications Dept.
Contacts: Corporate Communications Dept. Media Relations Group Tel: +81 (0)3-3273-0881 Fax: +81 (0)3-3281-6607 e-mail: pr@chugai-pharm.co.jp K ki Harada, Kouki H d Hiroshi Hi hi A Araki, ki Sachiyo S hi Yoshimura, Y hi Chi t Kitamura Chisato Kit Investor Relations Group p Tel: +81 (0)3-3273-0554 Fax
Chugai Pharmaceutical — Q1 2014 Earnings Presentation on 6ix